NCT06068400 2026-03-17
Clinical Study to Evaluate the Safety and Efficacy of CAR-T in the Treatment of Relapsed or Refractory Multiple Myeloma
Guangzhou Bio-gene Technology Co., Ltd
Phase NA Terminated
Clinical Trials
12 trialsNCT04827563 2026-03-04
Dyspnea and Cardiotoxicity in Multiple Myeloma Patients Who Receive Carfilzomib
University of Chicago
Terminated
NCT03031730 2026-02-10
Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Terminated
NCT03622775 2026-02-10
Daratumumab in Treating Participants With Relapsed Multiple Myeloma After Stem Cell Transplant
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT03374085 2026-02-09
A Safety, PK and Efficacy Study of CC-92480 Monotherapy and in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)
Celgene
Phase 1/2 Terminated
NCT03215030 2026-01-29
iinnovate-1
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT05556616 2026-01-29
iinnovate-2
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1 Terminated
NCT04716153 2026-01-20
RE-NEZ-SENS
University Hospital, Montpellier
Phase NA Terminated
NCT05172596 2026-01-13
PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma
Novartis
Phase 2 Terminated
NCT05675319 2026-01-05
AlloRelapseMM
Universitätsklinikum Hamburg-Eppendorf
Phase 3 Terminated
NCT04123418 2025-12-24
A Study of WVT078 in Patients With Multiple Myeloma (MM)
Novartis
Phase 1 Terminated
NCT04824794 2025-12-22
GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies
Genmab
Phase 1/2 Terminated